Please assess the completion status of the following clinical trial:

Trial Title: IMProving Executive Function Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female;~* Age 35-58;~* Have undergone risk-reducing bilateral salpingo-oophorectomy (RRSO) within the previous 15 years AND were premenopausal at the time of RRSO;~* Score of ≥ 20 on the Brown Attention Deficit Disorder Scale (BADDS);~* Onset of executive function difficulties occurred post RRSO;~* Clean urine drug screen (nicotine and marijuana are permissible);~* Are fluent in written and spoken English;~* Are able to give written informed consent (obtained at screening visit);~* Have a high school diploma or equivalent degree (i.e., GED), as per subject report;~* If using aromatase inhibitors or tamoxifen: Must have been on a stable dose for at least 6 months;~* If completing visits remotely: Must have access to a telecommunications application (i.e., Skype), email, scanner/fax machine, and a private area that enables the protection of participant confidentiality.~Exclusion criteria:~* Current, untreated psychiatric disorder;~* Substance use disorder within the previous 3 years;~* Lifetime history of ADHD or psychotic disorder including bipolar disorder, schizoaffective disorder, and schizophrenia;~* Lifetime history of stimulant abuse or dependence;~* Regular use of psychotropic medications except selective serotonin reuptake inhibitors (SSRI), serotonin noradrenergic reuptake inhibitors (SNRI), bupropion, zolpidem, gabapentin, or buspirone;~* Chemotherapy within the past year;~* Previous history of sensitivity or adverse reaction to lisdexamfetamine (LDX);~* History of seizures or unstable medical condition;~* Known heart disease or clinically significant abnormal electrocardiogram during screening as determined by the study MD;~* Uncontrolled hypertension;~* Presence of a metallic implant contraindicative to scanning at the 7T level;~* Claustrophobia.~* Consistent systolic blood pressure of \>145mm Hg or diastolic blood pressure \>90 mm Hg after three readings at time of screening;~* Known renal impairment and End Stage Renal Disease (ESRD).

- Gender: FEMALE
- Minimum Age: 35 Years
- Maximum Age: 58 Years
- Healthy Volunteers: t

Study Arms:
- Lisdexamfetamine, then Placebo (Type: EXPERIMENTAL): Participants will have a 50% chance of first receiving the active study medication. They will begin at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 6 weeks. After a washout period of 2 weeks they will begin with 1 sugar pill and will increase up to 3 pills after 4 weeks. Maximum time for taking the placebo is 6 weeks.
- Placebo, then Lisdexamfetamine (Type: EXPERIMENTAL): Participants will have a 50% chance of first receiving the placebo, beginning with 1 sugar pill and increasing up to 3 pills after 4 weeks. Maximum time for taking the placebo is 6 weeks. After a washout period of 2 weeks, they will begin active study medication at 20 mg/d and will increase up to 60 mg/d after 4 weeks, if well tolerated. Total time on the study drug is up to 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).